[Activity of the azole drugs in vitro against strains of Candida albicans with different codes isolated from the digestive tract in children].
The activity of ketoconazole (K, R04 1400 molecular weight 531.44), miconazole (M, R01 4889, molecular weight 479.15) and itraconazole (I, R05 1211, molecular weight 705.64) obtained from Janssen Pharmaceutica NV, against Candida albicans strains was studied. The axenic fungal strains were isolated from the faecal samples of children--not previously treated with antifungal drugs--with clinical symptoms suggesting the inflammation of the mucous membrane in the stomach and/or duodenum. The strains were assessed by own methods and unified tests (bioMérieux: API 20 C, API 20 C AUX). Five codes of Candida albicans Berkhout were found. The minimal inhibitory concentration (MIC) values were calculated from 448 dose-response curves according to the agar diffusion--Kadłubowski's method. MICs were also examined by analyzing the variation (min-max, x mean +/- standard error, mode Mo, median Me). It was demonstrated that all the strains used in the study were susceptible to the azoles drugs.
Kurnatowski
Marek
M
Klinika Gastroenterologii i Alergologii Dzieciecej Instytutu Pediatrii, Uniwersytet Medyczny, Lódź.
Kurnatowska
Alicja
A
Wasowska-Królikowska
Krystyna
K
D000293:Adolescent; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002176:Candida albicans / Q000145:classification* / Q000187:drug effects* / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D013045:Species Specificity
D000935:Antifungal Agents; D001393:Azoles